The Federal Circuit, in Pfizer, Inc. v. Ranbaxy Laboratories Ltd., 457 F.3d 1284 (Fed. Cir. August. 2, 2006), reversed the District Court holding that claim 6 directed to the hemicalicum salt of atorvastatin was valid even though it recognized there was a “technical problem” with the drafting of claim 6, because parent claim 2 recited only atorvastatin acid and the hemicalicum salt of atorvastatin acid is not an acid falling within the scope of claim 2. The Federal Circuit acknowledged that there may be ways to redraft claim 6 to cover the subject matter in a way that does not violate 112 ¶4, however the court, citing Nazomi Commc’ns, Inc. v. Arm Holdings, PLC, determined that court should not rewrite claims to preserve their validity.
About Lerner David
Lerner David specializes solely in intellectual property law. For over 55 years, Lerner David has thrived as an IP law firm, focusing on IP litigation, post grant proceedings, patent and trademark procurement, global IP asset management, licensing, due diligence and freedom-to-operate studies, privacy law and other IP rights. Lerner David is serving a diverse client base around the world, from start-ups to Global Fortune 500 companies, providing valuable global Intellectual Property strategies.